Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ Clinical Trial of Neoadjuvant Arterial Embolization Chemotherapy Combined Immune Checkpoint Inhibitor for Locally Advanced Rectal Cancer: A Single Arm Prospective Sturdy

NCT05420584 is registered in ClinicalTrials.gov with The Fourth Affiliated Hospital of Zhejiang University School of Medicine as lead sponsor.

NCT NCT05420584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05420584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ Clinical Trial of Neoadjuvant Arterial Embolization Chemotherapy Combined Immune Checkpoint Inhibitor for Locally Advanced Rectal Cancer: A Single Arm Prospective Sturdy
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Phase 2
Overall status
Unknown status
Start date
November 29, 2022
Completion date
October 31, 2025
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal neoplasms